Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade

12 Apr 2018

Abstract excerpt

Analyzing mouse tumor models in vivo, human T cells ex vivo, and human lung cancer samples, we provide direct evidence that NR2F6 acts as an immune checkpoint. Genetic ablation of Nr2f6, particularly in combination with established cancer immune checkpoint blockade, efficiently delays tumor progression and improves survival in experimental mouse models. The target genes deregulated in intratumoral T lymphocytes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29670099
DOI: 10.1038/s41467-018-04004-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockadePMID 29670099Read ↗

Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapySemantic proximity Read ↗

Insights into the emerging immune checkpoint NR2F6 in cancer immunitySemantic proximity Read ↗

Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6Semantic proximity Read ↗

Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapySemantic proximity Read ↗

Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunitySemantic proximity Read ↗

NR2F6 promotes the malignant progression of neuroblastoma as an indicator of poor prognosisSemantic proximity Read ↗

Reversible control of T cell exhaustion by NR4A transcription factors revealed through targeted protein degradationSemantic proximity Read ↗

RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunitySemantic proximity Read ↗

Pan-cancer analysis reveals the oncogenic and immunomodulatory roles of PTGFRN across human cancers.Semantic proximity Read ↗

Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer ImmunotherapySemantic proximity Read ↗

Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.Semantic proximity Read ↗

T cell-specific loss of IRF1 results in defective CD8 T cell activation and antitumor immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.